Download full-text PDF |
Source |
---|
Sci Rep
November 2024
Department of Cardiology, Jiading Branch of Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 800 Huangjiahuayuan Road, Shanghai, 201803, People's Republic of China.
This study investigates the impact of hemoglobin A1c on platelet reactivity and cardiovascular outcomes in patients undergoing drug-eluting stent implantation. HbA1c levels were categorized into 3 groups: < 6.5%, 6.
View Article and Find Full Text PDFRev Med Inst Mex Seguro Soc
May 2024
Instituto Mexicano del Seguro Social, Centro Médico Nacional del Bajío, Hospital de Especialidades No. 1, Servicio de Cardiología. León, Guanajuato, México.
Background: Mexico is the country with the highest mortality from acute myocardial infarction (AMI), which is why guidelines have been established for early reperfusion in which fibrinolysis is the second most accessible method. However, there is a percentage of patients who do not achieve acceptable myocardial perfusion and this is associated with adverse cardiovascular outcomes. Different adenosine schemes have been used as an adjuvant to restore adequate myocardial perfusion.
View Article and Find Full Text PDFInt J Cardiol
January 2025
Department of Cardiology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China. Electronic address:
Background: The no-reflow phenomenon is a significant complication during excimer laser coronary angioplasty (ELCA) procedures, which can lead to adverse outcomes. This study explores the efficacy of intracoronary administration of a cocktail solution comprising nitroglycerin, heparin, and verapamil on preventing no-reflow during ELCA in patients with in-stent restenosis (ISR).
Methods: This study included patients undergoing ELCA with contrast infusion for ISR.
EuroIntervention
September 2024
Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!